http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 07:35:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++Quoin+Pharmaceuticals%2C++++For%3A+Dec+31/26776738.html si-local-file:///var/storage/secattach/20260716/26776738.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++Quoin+Pharmaceuticals%2C++++For%3A+Dec+31/26776738.html Thu, 16 Jul 2026 07:35:00 -0400 2EB0 O.49219588 QNRX http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++Quoin+Pharmaceuticals%2C++++For%3A+Dec+31/26776738.html si-local-file:///var/storage/secattach/20260716/26776738.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++Quoin+Pharmaceuticals%2C++++For%3A+Dec+31/26776738.html Thu, 16 Jul 2026 07:35:00 -0400 2EB0 O.49219588 QNRX http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++Quoin+Pharmaceuticals%2C++++For%3A+Dec+31/26776738.html si-local-file:///var/storage/secattach/20260716/26776738.html http://www.streetinsider.com/SEC+Filings/Form++ARS++++++++Quoin+Pharmaceuticals%2C++++For%3A+Dec+31/26776738.html Thu, 16 Jul 2026 07:35:00 -0400 2EB0 O.49219588 QNRX http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+20/26776714.html si-local-file:///var/storage/secattach/20260716/26776714.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+20/26776714.html Thu, 16 Jul 2026 07:31:00 -0400 2EB0 O.49219588 QNRX http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+20/26776714.html si-local-file:///var/storage/secattach/20260716/26776714.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+20/26776714.html Thu, 16 Jul 2026 07:31:00 -0400 2EB0 O.49219588 QNRX http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+20/26776714.html si-local-file:///var/storage/secattach/20260716/26776714.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Quoin+Pharmaceuticals%2C++++For%3A+Aug+20/26776714.html Thu, 16 Jul 2026 07:31:00 -0400 2EB0 O.49219588 QNRX http://www.streetinsider.com/FDA/Quoin+gets+FDA+clearance+for+Phase+2+trial+of+QRX003+in+rare+skin+disease/26750679.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for QRX003 for the treatment of Peeling Skin Syndrome, allowing the company to proceed with a planned Phase 2 clinical study.</p> <p>The company submitted the IND on June 2, 2026, and received FDA clearance in July 2026. Quoin said it expects to initiate the Phase 2 study in the second half of 2026, with clinical sites, investigators, and study participants already identified.</p> <p>The Phase 2 study plans to enroll 6 to 8 pediatric and adult patients in the United States and Europe. http://www.streetinsider.com/FDA/Quoin+gets+FDA+clearance+for+Phase+2+trial+of+QRX003+in+rare+skin+disease/26750679.html Thu, 09 Jul 2026 08:30:20 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/FDA/Quoin+gets+FDA+clearance+for+Phase+2+trial+of+QRX003+in+rare+skin+disease/26750679.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for QRX003 for the treatment of Peeling Skin Syndrome, allowing the company to proceed with a planned Phase 2 clinical study.</p> <p>The company submitted the IND on June 2, 2026, and received FDA clearance in July 2026. Quoin said it expects to initiate the Phase 2 study in the second half of 2026, with clinical sites, investigators, and study participants already identified.</p> <p>The Phase 2 study plans to enroll 6 to 8 pediatric and adult patients in the United States and Europe. http://www.streetinsider.com/FDA/Quoin+gets+FDA+clearance+for+Phase+2+trial+of+QRX003+in+rare+skin+disease/26750679.html Thu, 09 Jul 2026 08:30:20 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/FDA/Quoin+gets+FDA+clearance+for+Phase+2+trial+of+QRX003+in+rare+skin+disease/26750679.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for QRX003 for the treatment of Peeling Skin Syndrome, allowing the company to proceed with a planned Phase 2 clinical study.</p> <p>The company submitted the IND on June 2, 2026, and received FDA clearance in July 2026. Quoin said it expects to initiate the Phase 2 study in the second half of 2026, with clinical sites, investigators, and study participants already identified.</p> <p>The Phase 2 study plans to enroll 6 to 8 pediatric and adult patients in the United States and Europe. http://www.streetinsider.com/FDA/Quoin+gets+FDA+clearance+for+Phase+2+trial+of+QRX003+in+rare+skin+disease/26750679.html Thu, 09 Jul 2026 08:30:20 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/FDA/Quoin+gets+FDA+clearance+for+Phase+2+trial+of+QRX003+in+rare+skin+disease/26750679.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for QRX003 for the treatment of Peeling Skin Syndrome, allowing the company to proceed with a planned Phase 2 clinical study.</p> <p>The company submitted the IND on June 2, 2026, and received FDA clearance in July 2026. Quoin said it expects to initiate the Phase 2 study in the second half of 2026, with clinical sites, investigators, and study participants already identified.</p> <p>The Phase 2 study plans to enroll 6 to 8 pediatric and adult patients in the United States and Europe. http://www.streetinsider.com/FDA/Quoin+gets+FDA+clearance+for+Phase+2+trial+of+QRX003+in+rare+skin+disease/26750679.html Thu, 09 Jul 2026 08:30:20 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/FDA/Quoin+gets+FDA+clearance+for+Phase+2+trial+of+QRX003+in+rare+skin+disease/26750679.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for QRX003 for the treatment of Peeling Skin Syndrome, allowing the company to proceed with a planned Phase 2 clinical study.</p> <p>The company submitted the IND on June 2, 2026, and received FDA clearance in July 2026. Quoin said it expects to initiate the Phase 2 study in the second half of 2026, with clinical sites, investigators, and study participants already identified.</p> <p>The Phase 2 study plans to enroll 6 to 8 pediatric and adult patients in the United States and Europe. http://www.streetinsider.com/FDA/Quoin+gets+FDA+clearance+for+Phase+2+trial+of+QRX003+in+rare+skin+disease/26750679.html Thu, 09 Jul 2026 08:30:20 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/FDA/Quoin+gets+FDA+clearance+for+Phase+2+trial+of+QRX003+in+rare+skin+disease/26750679.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for QRX003 for the treatment of Peeling Skin Syndrome, allowing the company to proceed with a planned Phase 2 clinical study.</p> <p>The company submitted the IND on June 2, 2026, and received FDA clearance in July 2026. Quoin said it expects to initiate the Phase 2 study in the second half of 2026, with clinical sites, investigators, and study participants already identified.</p> <p>The Phase 2 study plans to enroll 6 to 8 pediatric and adult patients in the United States and Europe. http://www.streetinsider.com/FDA/Quoin+gets+FDA+clearance+for+Phase+2+trial+of+QRX003+in+rare+skin+disease/26750679.html Thu, 09 Jul 2026 08:30:20 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/FDA/Quoin+gets+FDA+clearance+for+Phase+2+trial+of+QRX003+in+rare+skin+disease/26750679.html <p>Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for QRX003 for the treatment of Peeling Skin Syndrome, allowing the company to proceed with a planned Phase 2 clinical study.</p> <p>The company submitted the IND on June 2, 2026, and received FDA clearance in July 2026. Quoin said it expects to initiate the Phase 2 study in the second half of 2026, with clinical sites, investigators, and study participants already identified.</p> <p>The Phase 2 study plans to enroll 6 to 8 pediatric and adult patients in the United States and Europe. http://www.streetinsider.com/FDA/Quoin+gets+FDA+clearance+for+Phase+2+trial+of+QRX003+in+rare+skin+disease/26750679.html Thu, 09 Jul 2026 08:30:20 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html <ul><li style="list-style-position:inside; text-align:center;"><em>Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and Europe</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>FDA Expressed No Safety Concerns Over Study Design and Duration of Dosing</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>First-Ever Formal Clinical Study for a Potential Peeling Skin Syndrome Therapy</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Second Cleared IND Indication for QRX003, in Addition to Netherton Syndrome</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Peeling Skin Syndrome Currently Has No Approved Treatment</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Quoin Anticipates Also Testing QRX003 in Additional Ichthyosis Indications for Which There Are No Approved Treatments<br/><br/></em></li></ul> <p>ASHBURN, Va., July http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html Thu, 09 Jul 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html <ul><li style="list-style-position:inside; text-align:center;"><em>Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and Europe</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>FDA Expressed No Safety Concerns Over Study Design and Duration of Dosing</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>First-Ever Formal Clinical Study for a Potential Peeling Skin Syndrome Therapy</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Second Cleared IND Indication for QRX003, in Addition to Netherton Syndrome</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Peeling Skin Syndrome Currently Has No Approved Treatment</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Quoin Anticipates Also Testing QRX003 in Additional Ichthyosis Indications for Which There Are No Approved Treatments<br/><br/></em></li></ul> <p>ASHBURN, Va., July http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html Thu, 09 Jul 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html <ul><li style="list-style-position:inside; text-align:center;"><em>Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and Europe</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>FDA Expressed No Safety Concerns Over Study Design and Duration of Dosing</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>First-Ever Formal Clinical Study for a Potential Peeling Skin Syndrome Therapy</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Second Cleared IND Indication for QRX003, in Addition to Netherton Syndrome</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Peeling Skin Syndrome Currently Has No Approved Treatment</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Quoin Anticipates Also Testing QRX003 in Additional Ichthyosis Indications for Which There Are No Approved Treatments<br/><br/></em></li></ul> <p>ASHBURN, Va., July http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html Thu, 09 Jul 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html <ul><li style="list-style-position:inside; text-align:center;"><em>Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and Europe</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>FDA Expressed No Safety Concerns Over Study Design and Duration of Dosing</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>First-Ever Formal Clinical Study for a Potential Peeling Skin Syndrome Therapy</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Second Cleared IND Indication for QRX003, in Addition to Netherton Syndrome</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Peeling Skin Syndrome Currently Has No Approved Treatment</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Quoin Anticipates Also Testing QRX003 in Additional Ichthyosis Indications for Which There Are No Approved Treatments<br/><br/></em></li></ul> <p>ASHBURN, Va., July http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html Thu, 09 Jul 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html <ul><li style="list-style-position:inside; text-align:center;"><em>Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and Europe</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>FDA Expressed No Safety Concerns Over Study Design and Duration of Dosing</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>First-Ever Formal Clinical Study for a Potential Peeling Skin Syndrome Therapy</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Second Cleared IND Indication for QRX003, in Addition to Netherton Syndrome</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Peeling Skin Syndrome Currently Has No Approved Treatment</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Quoin Anticipates Also Testing QRX003 in Additional Ichthyosis Indications for Which There Are No Approved Treatments<br/><br/></em></li></ul> <p>ASHBURN, Va., July http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html Thu, 09 Jul 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html <ul><li style="list-style-position:inside; text-align:center;"><em>Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and Europe</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>FDA Expressed No Safety Concerns Over Study Design and Duration of Dosing</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>First-Ever Formal Clinical Study for a Potential Peeling Skin Syndrome Therapy</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Second Cleared IND Indication for QRX003, in Addition to Netherton Syndrome</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Peeling Skin Syndrome Currently Has No Approved Treatment</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Quoin Anticipates Also Testing QRX003 in Additional Ichthyosis Indications for Which There Are No Approved Treatments<br/><br/></em></li></ul> <p>ASHBURN, Va., July http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html Thu, 09 Jul 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html <ul><li style="list-style-position:inside; text-align:center;"><em>Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and Europe</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>FDA Expressed No Safety Concerns Over Study Design and Duration of Dosing</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>First-Ever Formal Clinical Study for a Potential Peeling Skin Syndrome Therapy</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Second Cleared IND Indication for QRX003, in Addition to Netherton Syndrome</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Peeling Skin Syndrome Currently Has No Approved Treatment</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Quoin Anticipates Also Testing QRX003 in Additional Ichthyosis Indications for Which There Are No Approved Treatments<br/><br/></em></li></ul> <p>ASHBURN, Va., July http://www.streetinsider.com/Press+Releases/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html Thu, 09 Jul 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html <ul><li style="list-style-position:inside; text-align:center;"><em>Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and Europe</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>FDA Expressed No Safety Concerns Over Study Design and Duration of Dosing</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>First-Ever Formal Clinical Study for a Potential Peeling Skin Syndrome Therapy</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Second Cleared IND Indication for QRX003, in Addition to Netherton Syndrome</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Peeling Skin Syndrome Currently Has No Approved Treatment</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Quoin Anticipates Also Testing QRX003 in Additional Ichthyosis Indications for Which There Are No Approved Treatments<br/><br/></em></li></ul> <p>ASHBURN, Va., July http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html Thu, 09 Jul 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html <ul><li style="list-style-position:inside; text-align:center;"><em>Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and Europe</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>FDA Expressed No Safety Concerns Over Study Design and Duration of Dosing</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>First-Ever Formal Clinical Study for a Potential Peeling Skin Syndrome Therapy</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Second Cleared IND Indication for QRX003, in Addition to Netherton Syndrome</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Peeling Skin Syndrome Currently Has No Approved Treatment</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Quoin Anticipates Also Testing QRX003 in Additional Ichthyosis Indications for Which There Are No Approved Treatments<br/><br/></em></li></ul> <p>ASHBURN, Va., July http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html Thu, 09 Jul 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html <ul><li style="list-style-position:inside; text-align:center;"><em>Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and Europe</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>FDA Expressed No Safety Concerns Over Study Design and Duration of Dosing</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>First-Ever Formal Clinical Study for a Potential Peeling Skin Syndrome Therapy</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Second Cleared IND Indication for QRX003, in Addition to Netherton Syndrome</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Peeling Skin Syndrome Currently Has No Approved Treatment</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Quoin Anticipates Also Testing QRX003 in Additional Ichthyosis Indications for Which There Are No Approved Treatments<br/><br/></em></li></ul> <p>ASHBURN, Va., July http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html Thu, 09 Jul 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html <ul><li style="list-style-position:inside; text-align:center;"><em>Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and Europe</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>FDA Expressed No Safety Concerns Over Study Design and Duration of Dosing</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>First-Ever Formal Clinical Study for a Potential Peeling Skin Syndrome Therapy</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Second Cleared IND Indication for QRX003, in Addition to Netherton Syndrome</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Peeling Skin Syndrome Currently Has No Approved Treatment</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Quoin Anticipates Also Testing QRX003 in Additional Ichthyosis Indications for Which There Are No Approved Treatments<br/><br/></em></li></ul> <p>ASHBURN, Va., July http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html Thu, 09 Jul 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html <ul><li style="list-style-position:inside; text-align:center;"><em>Quoin Expects to Initiate Phase 2 Study in 2H 2026, Study Plans to Enroll 6-8 Pediatric and Adult Patients in the U.S. and Europe</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>FDA Expressed No Safety Concerns Over Study Design and Duration of Dosing</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>First-Ever Formal Clinical Study for a Potential Peeling Skin Syndrome Therapy</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Second Cleared IND Indication for QRX003, in Addition to Netherton Syndrome</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Peeling Skin Syndrome Currently Has No Approved Treatment</em></li><li style="list-style-position:inside; margin-bottom:4pt; text-align:center;"><em>Quoin Anticipates Also Testing QRX003 in Additional Ichthyosis Indications for Which There Are No Approved Treatments<br/><br/></em></li></ul> <p>ASHBURN, Va., July http://www.streetinsider.com/Globe+Newswire/Quoin+Pharmaceuticals+Receives+FDA+IND+Clearance+to+Initiate+Phase+2+Study+of++QRX003+in+Peeling+Skin+Syndrome/26750656.html Thu, 09 Jul 2026 08:30:00 -0400 2EB0 A.06822034 A.50216923 O.20026344 O.49219588 O.57185041 QNRX